Literature DB >> 15972541

Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain.

Eric T Harvill1, Gloria Lee, Vanessa K Grippe, Tod J Merkel.   

Abstract

Concerns regarding safety and control of virulent Bacillus anthracis have created substantial hurdles to the study of anthrax. The Sterne strain is considered relatively safe to study, but this acapsular strain has a defect in normal mice and is often studied in A/J mice. A/J mice are highly susceptible to the Sterne strain, due to a defect in the Hc locus, which encodes complement factor 5 (C5). Here we show that normally resistant C57BL/6 mice become highly susceptible to the Sterne strain upon complement depletion with cobra venom factor. This generalizable approach should allow the virulence of anthrax to be studied under relatively safe conditions and using a wide variety of mouse strains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972541      PMCID: PMC1168577          DOI: 10.1128/IAI.73.7.4420-4422.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Differences in susceptibility of inbred mice to Bacillus anthracis.

Authors:  S L Welkos; T J Keener; P H Gibbs
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

2.  Cytokine response to infection with Bacillus anthracis spores.

Authors:  Alison K Pickering; Manuel Osorio; Gloria M Lee; Vanessa K Grippe; Mechelle Bray; Tod J Merkel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 3.  Anthrax.

Authors:  M Mock; A Fouet
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

4.  Modulation of mouse endotoxic fever by complement.

Authors:  S Li; V M Holers; S A Boackle; C M Blatteis
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

5.  Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.

Authors:  Scott Shapiro; David O Beenhouwer; Marta Feldmesser; Carlos Taborda; Michael C Carroll; Arturo Casadevall; Matthew D Scharff
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 6.  Structure and function of anthrax toxin.

Authors:  D B Lacy; R J Collier
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

7.  Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.

Authors:  S L Welkos; N J Vietri; P H Gibbs
Journal:  Microb Pathog       Date:  1993-05       Impact factor: 3.738

Review 8.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

9.  Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis.

Authors:  S L Welkos; A M Friedlander
Journal:  Microb Pathog       Date:  1988-01       Impact factor: 3.738

Review 10.  The roles of anthrax toxin in pathogenesis.

Authors:  Mahtab Moayeri; Stephen H Leppla
Journal:  Curr Opin Microbiol       Date:  2004-02       Impact factor: 7.934

  10 in total
  28 in total

1.  Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection.

Authors:  Christopher K Cote; Nico Van Rooijen; Susan L Welkos
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Cathelicidin administration protects mice from Bacillus anthracis spore challenge.

Authors:  Mark W Lisanby; Melissa K Swiecki; Brian L P Dizon; Kathryn J Pflughoeft; Theresa M Koehler; John F Kearney
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Activation of the classical complement pathway by Bacillus anthracis is the primary mechanism for spore phagocytosis and involves the spore surface protein BclA.

Authors:  Chunfang Gu; Sarah A Jenkins; Qiong Xue; Yi Xu
Journal:  J Immunol       Date:  2012-03-21       Impact factor: 5.422

4.  Human transferrin confers serum resistance against Bacillus anthracis.

Authors:  Suzan H M Rooijakkers; Suzanne L Rasmussen; Shauna M McGillivray; Thomas B Bartnikas; Anne B Mason; Arthur M Friedlander; Victor Nizet
Journal:  J Biol Chem       Date:  2010-07-08       Impact factor: 5.157

5.  Multigenic control and sex bias in host susceptibility to spore-induced pulmonary anthrax in mice.

Authors:  Jagjit S Yadav; Suman Pradhan; Renuka Kapoor; Hansraj Bangar; Benjamin B Burzynski; Daniel R Prows; Linda Levin
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

6.  Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.

Authors:  Matthew A Crawford; Yinghua Zhu; Candace S Green; Marie D Burdick; Patrick Sanz; Farhang Alem; Alison D O'Brien; Borna Mehrad; Robert M Strieter; Molly A Hughes
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

7.  Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model.

Authors:  Hitendra S Chand; Melissa Drysdale; Julie Lovchik; Theresa M Koehler; Mary F Lipscomb; C Rick Lyons
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

8.  Nod1/Nod2-mediated recognition plays a critical role in induction of adaptive immunity to anthrax after aerosol exposure.

Authors:  Crystal L Loving; Manuel Osorio; Yun-Gi Kim; Gabriel Nuñez; Molly A Hughes; Tod J Merkel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

9.  Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.

Authors:  Dennis M Klinman; Debra Currie; Gloria Lee; Vanessa Grippe; Tod Merkel
Journal:  Microbes Infect       Date:  2007-08-10       Impact factor: 2.700

10.  Bacillus anthracis spores and lethal toxin induce IL-1beta via functionally distinct signaling pathways.

Authors:  Tae Jin Kang; Subhendu Basu; Lei Zhang; Karen E Thomas; Stefanie N Vogel; Les Baillie; Alan S Cross
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.